112 related articles for article (PubMed ID: 19500133)
1. Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome.
Xu W; Zhou L; Qin R; Tang H; Shen H
Eur J Haematol; 2009 Oct; 83(4):313-9. PubMed ID: 19500133
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer.
Huang X; Ushijima K; Komai K; Takemoto Y; Motoshima S; Kamura T; Kohno K
Gynecol Oncol; 2004 May; 93(2):287-91. PubMed ID: 15099935
[TBL] [Abstract][Full Text] [Related]
3. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
4. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma.
Oda Y; Sakamoto A; Shinohara N; Ohga T; Uchiumi T; Kohno K; Tsuneyoshi M; Kuwano M; Iwamoto Y
Clin Cancer Res; 1998 Sep; 4(9):2273-7. PubMed ID: 9748149
[TBL] [Abstract][Full Text] [Related]
6. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
[TBL] [Abstract][Full Text] [Related]
7. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 associated athanogene-1 overexpression in diffuse large B-cell lymphoma.
Ataollahi M; Salehi M; Doostan I; Kabiri Z; Mohajeri M; Mahmoodi F; Shokouhi R; Javan S; Meshkibaf MH; Miladpoor B
Iran J Immunol; 2008 Jun; 5(2):124-30. PubMed ID: 18523358
[TBL] [Abstract][Full Text] [Related]
10. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
Rodig SJ; Savage KJ; LaCasce AS; Weng AP; Harris NL; Shipp MA; Hsi ED; Gascoyne RD; Kutok JL
Am J Surg Pathol; 2007 Jan; 31(1):106-12. PubMed ID: 17197926
[TBL] [Abstract][Full Text] [Related]
11. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma.
Yasen M; Kajino K; Kano S; Tobita H; Yamamoto J; Uchiumi T; Kon S; Maeda M; Obulhasim G; Arii S; Hino O
Clin Cancer Res; 2005 Oct; 11(20):7354-61. PubMed ID: 16243807
[TBL] [Abstract][Full Text] [Related]
12. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
[TBL] [Abstract][Full Text] [Related]
13. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
[TBL] [Abstract][Full Text] [Related]
14. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
15. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
Kim SJ; Lee SJ; Sung HJ; Choi IK; Choi CW; Kim BS; Kim JS; Yu W; Hwang HS; Kim IS
Acta Haematol; 2008; 120(4):211-6. PubMed ID: 19153476
[TBL] [Abstract][Full Text] [Related]
16. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
[TBL] [Abstract][Full Text] [Related]
17. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
18. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
19. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.
Shim HK; Lee WW; Park SY; Kim H; So Y; Kim SE
Nucl Med Biol; 2009 Feb; 36(2):191-7. PubMed ID: 19217531
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis.
Hasselblom S; Hansson U; Sigurdardottir M; Nilsson-Ehle H; Ridell B; Andersson PO
Pathol Int; 2008 Aug; 58(8):529-32. PubMed ID: 18705775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
